Biomodulin T: a new therapeutic option against COVID-19

Authors

Keywords:

immunity, Biomodulin T

Abstract

To boost immunity in people with gradual deterioration of the immune system, caused by aging or suffering from different comorbidities, the Group of the Biotechnology and Pharmaceutical Industries of Cuba (Biotechnology Farma) has introduced the product Biomodulin T. This has also been used as part of the prevention protocol and for the treatment of patients positive to SARS-CoV-2. Thymus-dependent immunity, including T-cell immunity and antibody production, decreases with organ size in adults, which is known as “immunosenescence.” Biomodulin T is a diafiltered extract of veal thymus; it has a cytorestaurative and immunomodulatory action, which has demonstrated its effectiveness in different risk groups, within which elder people occupy a special place. In the current national and international epidemiological situation its inclusion in the protocols of action is significant. The use of this medication in a vulnerable group, such as elder people, represents a hopeful horizon as progress is made in the production of safe and effective national vaccines.

Downloads

Download data is not yet available.

Author Biographies

José Alberto Afonso-de-León, Universidad de Ciencias Médicas de Matanzas. Matanzas

Doctor en Ciencias Médicas. Departamento de Posgrado

Odalys Sánchez-Barrera, Universidad de Ciencias Médicas de Matanzas. Matanzas

Vicedecana General.

References

1. Ministerio de Salud Pública. Protocolo de actuación nacional para la COVID-19 [Internet]. La Habana: Ministerio de Salud Pública; 2020 [citado 03/02/2021]. 215 p. Disponible en: https://files.sld.cu/editorhome/files/2021/03/VERSION_FINAL_6_EXTENDIDA_PROTOCOLO_REVISADA_28_MARZO__2021.pdf

2. Díaz-Canel-Bermúdez M, Núñez-Jover J. Gestión gubernamental y ciencia cubana en el enfrentamiento a la COVID-19. Anales de la Academia de Ciencias de Cuba [Internet]. 2020 [citado 03/02/2021];10(2). Disponible en: http://www.revistaccuba.cu/index.php/revacc/article/view/881/893

3. Martínez-Díaz E, Pérez-Rodríguez R, Herrera-Martínez L, et al. La industria biofarmacéutica cubana en el combate contra la pandemia de COVID-19. Anales de la Academia de Ciencias de Cuba [Internet]. 2020 [citado 03/02/2021];10(2): [aprox. 12 p.]. Disponible en: http://www.revistaccuba.cu/index.php/revacc/article/view/906/894

4. BioCubaFarma. Medicamentos biológicos innovadores. La Habana: BioCubaFarma; 2020. 16 p.

5. Organización Mundial de la Salud. Uso de Biomodulina T para la prevención de infecciones, incluido COVID-19 en adultos mayores. Ensayo clínico de fase IV. Plataforma internacional de registro de ensayos clínicos [Internet]. Ginebra: OMS; 2020 [citado 03/02/2021]. 9 p. Disponible en: https://rpcec.sld.cu/ensayos/RPCEC00000310-Sp

6. Suárez-Formigo GM, Saavedra-Hernández D. Biomodulina T May Restore Immunity in Older Adults. Medicc Review [Internet]. 2020 [citado 03/02/2021];22(3):54-6. Disponible en: https://mediccreview.org/biomodulina-t-may-restore-immunity-in-older-adults/

7. Fulop T, Larbi A, Dupuis G, et al. Immunosenescence and Inflamm-Aging As Two Sides of the Same Coin: Friends or Foes? Front Immunol. 2018 Jan 10;8:1960. Citado en PubMed; PMID: 29375577.

8. Rodríguez-Martín RR, González-González O, Rodríguez-González C, et al. Biomodulina T (InmunyVital®) Restores T Cells and Helps Contain COVID-19. Front Immunol. 2020 Dec 9;11:606447. Citado en PubMed; PMID: 33362793.

9. Saavedra D, Fuertes SA, Suárez GM, et al. Biomodulina T partially restores immunosenescent CD4 and CD8 T cell compartments in the elderly. Exp Gerontol. 2019 Sept;124:110633. Citado en PubMed; PMID: 31207285.

10. World Health Organization. Clinical management of COVID-19: interim guidance, 27 May 2020. Ginebra: World Health Organization; 2020 [citado 03/02/2021]. Disponible en: https://apps.who.int/iris/handle/10665/332196

11. Centro para el Control Estatal de Medicamentos, Equipos y Dispositivos Médicos (CECMED). Biomodulina® T (fracción tímica). Rev Cubana Farm [Internet]. 2020 [citado 03/02/2021];53(3):e469. Disponible en: http://www.revfarmacia.sld.cu/index.php/far

12. Lara-Rodríguez RF, Rodríguez R, Vargas-Batista A, et al. Efectos adversos por el uso de la biomodulina T y la corticotropina en pacientes con esclerosis múltiple. Medisur [Internet]. 2007 [citado 03/02/2021];5(1):65-72. Disponible en: http://www.medisur.sld.cu/index.php/medisur/article/view/253

Downloads

Published

2021-12-15

How to Cite

1.
Afonso-de-León JA, Sánchez-Barrera O, Rodríguez-Curbelo M, García-García D, Cañete-Villafranca R. Biomodulin T: a new therapeutic option against COVID-19. Rev Méd Electrón [Internet]. 2021 Dec. 15 [cited 2025 Jan. 30];43(6):1-6. Available from: https://revmedicaelectronica.sld.cu/index.php/rme/article/view/4422

Issue

Vol. 43 No. 6 (2021)

Section

Opinion article

License

All content published in this journal is Open Access, distributed under the terms of the CC BY-NC 4.0 License.

It allows:

 - Copy and redistribute published material in any medium or format.

 - Adapt the content.

 This will be done under the following terms:

 - Attribute the authors' credits and indicate whether changes were made, in which case it must be in a reasonable way.

 - Non-commercial use.

 - Recognize the journal where it is published.

 The copyrights of each article are maintained, without restrictions.

Most read articles by the same author(s)

1 2 > >>